Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds - Summary - MDSpire
Feature

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

Combining a visual inspection of the bladder—systematic endoscopic evaluation—with a blood test to check for the presence of ctDNA may accurately predict which patients with bladder cancer still have ...

Share

Dr. Matthew R. Zilbelman presented research at the 2026 ASCO Genitourinary Cancers Symposium demonstrating that combining visual inspection of the bladder with blood tests for circulating tumor DNA (ctDNA) can more accurately predict remaining cancer in bladder cancer patients post-treatment. This dual approach may help identify patients who can forgo cystectomy, reducing unnecessary surgeries. The study found that this method enhanced detection to 95% accuracy, far surpassing traditional methods, and significantly improved patient prognosis regarding cancer recurrence and survival.

Original Source(s)

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

  • by The ASCO Post Staff

  • April 7, 2026

Related Content

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...